Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

Telebressive: The Evolutionary Food Chain in the Sector

We're very positive into some really great top line results, benefit on spleen volume, benefit on symptom score, low toxicity addition to jackify alone. That is a telebressive being better than their competitor. But we also think that there's a lot of strategic optionality. Once you've got a de-risked asset that everybody says it's synergistic with the standard of care and it leads to a lot better patient outcomes, that's going to be very valuable. And so if they showed good top line results in December, then you're talking about from then end of year 24 when they're getting approved.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner